Analysts have estimated the hemp-CBD market to hit 22 billion by 2022, as consumers around the world increasingly looking to CBD oils, edibles, and other products to help treat chronic pain conditions and as a potential preventative measure for muscle soreness and inflammation. CBD sales are booming today, as growers of hemp ramp up production in response to increasing demand.
Cannabis legalization is sweeping over North America, 10 states plus Washington, D.C., have all legalized recreational marijuana over the last few years, but 2020 may lead to a few more joining them.
The Cannabis sector has shown exciting promise in terms of opportunities for investors looking to the space, significant investments, improved distribution and refined marketing strategies mean theses public cannabis companies are only just starting to sprout. Cannabis stock investors are looking for the industry to deliver improvement this year.
For investors ready to jump on the hemp CBD bandwagon, Can B Corp. (OTCQB: CANB) is a stock to consider buying at these levels.
Can B Corp. (OTCQB: CANB) is a Health & Wellness company providing the highest quality cannabidiol (CBD) products under the brands of Canbiola, Seven Chakras, NuWellness, Pure Leaf Oil and Duramed. Can B utilizes multi-channel distribution to reach consumers, including medical facilities, doctor offices, retailers, online and direct. Can B is also an exclusive partner of the LifeGuard® Brand in developing a line of consumer products. The Company is also launching Super Foods, a line of nutritional supplements. Can B Corp. owns and operates an R&D and production facility in Lacey, WA, and Green Grow Farms, a licensed hemp grow and cultivation in New York.
Last week, the company announced its collaboration with Dr. Karl Zarse in launching ImmuneX2, a super immune boosting AM/PM supplement. According to Dr. Zarse, ImmuneX2 ingredients are correlated with optimizing your immune system before you need it. The Company is expecting to start shipping ImmuneX2 by the end of November.
ImmuneX2 is a high concentration immune booster and is positioned for AM/PM dosing for consistent serum concentration. It’s pre-packaged for maximum convenience and offers free member access for ongoing education that updates in real-time. The physician-developed immunity optimization formula has both innate and adaptive immune functionality specifically targeted with ImmuneX2’s proprietary customer blend focused on immune system optimization.
According to Dr. Zarse, no other product exceeds the dosages of this blend while avoiding any issues of toxicity. It can compensate for variations in the client base including malabsorption issues, size differences, and baseline health status. Maximum benefit is obtained not only by staying adherent to the daily supplement line but also by following and learning an online education program.
CANB has soared over 500% last May/June, the best gain on the CBD product maker, and several upcoming catalysts could catapult Can B Corp. (OTCQB: CANB) shares higher. In our view, a bounce is all but guaranteed.